3/2
08:28 am
huma
Humacyte To Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Humacyte To Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/2
08:00 am
huma
Humacyte To Participate in Upcoming Investor Conferences
Low
Report
Humacyte To Participate in Upcoming Investor Conferences
2/19
08:23 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/18
08:00 am
huma
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
Low
Report
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
2/18
03:27 am
huma
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential [Yahoo! Finance]
Medium
Report
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential [Yahoo! Finance]
2/9
06:09 pm
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research.
High
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research.
2/9
05:10 pm
huma
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]
High
Report
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]
2/9
02:45 pm
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/9
08:00 am
huma
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
High
Report
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
1/21
10:38 am
huma
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
1/8
08:00 am
huma
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
Medium
Report
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
1/7
11:58 am
huma
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
1/5
08:42 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
1/5
08:06 am
huma
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel [Yahoo! Finance]
Medium
Report
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel [Yahoo! Finance]
1/5
08:00 am
huma
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
Medium
Report
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
12/22
10:25 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
12/22
08:10 am
huma
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair [Yahoo! Finance]
Medium
Report
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair [Yahoo! Finance]
12/22
08:00 am
huma
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
Medium
Report
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
12/21
01:08 am
huma
Medium
Report
12/16
04:37 pm
huma
Humacyte (NASDAQ:HUMA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:00 am
huma
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Medium
Report
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
12/13
01:10 am
huma
Medium
Report
12/10
02:22 pm
huma
Humacyte (HUMA): Benchmark Remains Bullish on Stock [Yahoo! Finance]
Low
Report
Humacyte (HUMA): Benchmark Remains Bullish on Stock [Yahoo! Finance]